NEWS
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-free at 26 weeks.
3. 100% of 6E10 difluprednate-alone patients had no or minimal inflammation.
4. 88% of patients preferred Ixo-vec over prior anti-VEGF injections.
5. Efficacy and safety with 6E10 at 26 weeks were similar to or better than OPTIC at 2E11.
The company plans to present 9-month data and pivotal trial design updates in Q4 2024, with Phase 3 trials expected to begin in H1 2025.
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-free at 26 weeks.
3. 100% of 6E10 difluprednate-alone patients had no or minimal inflammation.
4. 88% of patients preferred Ixo-vec over prior anti-VEGF injections.
5. Efficacy and safety with 6E10 at 26 weeks were similar to or better than OPTIC at 2E11.
The company plans to present 9-month data and pivotal trial design updates in Q4 2024, with Phase 3 trials expected to begin in H1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1619Followers
87Following
12KVisitors
Follow